Compare Halliburton Company (HAL) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Johnson & Johnson — how do they compare? Halliburton Company trades at $32.68 (market cap $27.14B), while Johnson & Johnson trades at $259.14 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 22.8× Halliburton Company's market cap, and Johnson & Johnson is trading nearer its 52-week high, Halliburton Company nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Johnson & Johnson for 129 Days on average.
| HAL | JNJ | |
|---|---|---|
Market Cap | $27.14B | $618.09B |
Volume | 11,258,156 | 6,050,983 |
Sector | Energy | Health |
52-Week High | $42.98 | $278.43 |
52-Week Low | $21.82 | $186.00 |
Typical Hold Time | 89 Days | 129 Days |
Enterprise Value | $33.29B | $646.37B |
Dividend Yield | 2.09% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.75, down 2.96% on the day, reflecting near-term bearish technical signals despite strong analyst support. The stock shows solid fundamentals with a P/E of 17.05 and consistent earnings beats in recent quarters. Recent news highlights expansion in Venezuela and a new contract in Cyprus, positioning the company for growth in international energy markets. Cash flow trends indicate variability, with 2025 net cash flow negative but projected to turn positive in 2026.
The outlook for HAL is cautiously optimistic, driven by international contracts and analyst consensus pointing to significant upside with a $43.11 price target. Key risks include oil price volatility and execution challenges in new markets. Investment opportunity lies in the company's strategic expansions and robust profitability metrics, though investors should weigh macroeconomic factors affecting the energy sector.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
